Lei Yongfa, Liang Xiaotian, Zhu Hua, Wang Jin, Zhang Xiaochen, Duan Siliang, Liang Weiming
The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Medicine College, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Front Immunol. 2025 Jul 24;16:1586914. doi: 10.3389/fimmu.2025.1586914. eCollection 2025.
This meta-analysis aimed to evaluate the efficacy and safety of Lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors (PD-1 inhibitors) in the treatment of intermediate or advanced hepatocellular carcinoma (HCC).
Four databases (Pubmed, Embase, Web of Science, and Cochrane Library) were searched for studies comparing lenvatinib plus transarterial chemoembolization with PD-1 inhibitors (TACE-L-P) versus Lenvatinib plus transarterial chemoembolization (TACE-L) for intermediate or advanced HCC. Meta-analyses were conducted for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and Grade ≥ 3 treatment-related adverse events (Grade ≥ 3 AEs).
The meta-analysis comprised 19 retrospective cohort studies, including of 2002 patients diagnosed with intermediate or advanced HCC. In this cohort, 1011 individuals were administered TACE-L-P, while 991 patients received TACE-L. In comparison to TACE-L, TACE-L-P demonstrated a superior ORR [odds ratio (OR) = 2.38, 95% confidence interval (CI) 1.98 ~ 2.87, P < 0.00001] and DCR (OR = 3.22, 95% CI, 2.32 ~ 4.45, P < 0.00001). TACE-L-P showed superior efficacy compared to TACE-L regarding PFS (HR: 0.56, 95%CI 0.50 to 0.62, P<0.0001) and OS (HR: 0.70, 95%CI 0.60 to 0.80, P<0.0001). Regarding safety, the incidence of Grade ≥ 3 AEs was more prevalent in the TACE-L-P group compared to the TACE-L group (OR=1.58, 95% CI: 1.27 ~ 1.97, P<0.0001).
The present meta-analysis present a comparison of the efficacy and safety of TACE-L-P against TACE-L for intermediate or advanced HCC. TACE-L-P enhanced ORR, DCR, PFS, and OS relative to TACE-L. Furthermore, the improved efficacy of TACE-L-P was correlated with a rise in the incidence of Grade ≥ 3 AEs.
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024590414, identifier CRD42024590414.
本荟萃分析旨在评估乐伐替尼联合经动脉化疗栓塞术（无论是否联合程序性死亡-1抑制剂（PD-1抑制剂））治疗中晚期肝细胞癌（HCC）的疗效和安全性。
检索四个数据库（PubMed、Embase、Web of Science和Cochrane图书馆），查找比较乐伐替尼联合经动脉化疗栓塞术联合PD-1抑制剂（TACE-L-P）与乐伐替尼联合经动脉化疗栓塞术（TACE-L）治疗中晚期HCC的研究。对无进展生存期（PFS）、总生存期（OS）、客观缓解率（ORR）、疾病控制率（DCR）和≥3级治疗相关不良事件（≥3级AE）进行荟萃分析。
该荟萃分析纳入了19项回顾性队列研究，包括2002例诊断为中晚期HCC的患者。在该队列中，1011例患者接受了TACE-L-P治疗，而991例患者接受了TACE-L治疗。与TACE-L相比，TACE-L-P显示出更高的ORR（优势比（OR）=2.38，95%置信区间（CI）1.982.87，P<0.00001）和DCR（OR=3.22，95%CI，2.324.45，P<0.00001）。在PFS（HR：0.56，95%CI 0.50至0.62，P<0.0001）和OS（HR：0.70，95%CI 0.60至0.80，P<0.0001）方面，TACE-L-P显示出比TACE-L更好的疗效。在安全性方面，≥3级AE的发生率在TACE-L-P组比TACE-L组更普遍（OR=1.58，95%CI：1.27~1.97，P<0.0001）。
本荟萃分析比较了TACE-L-P与TACE-L治疗中晚期HCC的疗效和安全性。与TACE-L相比，TACE-L-P提高了ORR、DCR、PFS和OS。此外，TACE-L-P疗效的提高与≥3级AE发生率的增加相关。
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024590414，标识符CRD42024590414。
Zotero 插件
